Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
EN | CN

You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-DNA-PK-M3814
M3814

Chemical Structure : M3814

CAS No.: 1637542-33-6

M3814 (Peposertib; Nedisertib; M 3814; MSC2490484A)

Catalog No.: PC-61389Not For Human Use, Lab Use Only.

M3814 (Nedisertib, Peposertib, MSC2490484A) is a highly potent, selective, ATP-competitive and orally bioavailable inhibitor of DNA-PK with IC50 of 0.6 nM (10 uM ATP).

Packing Price Stock Quantity
5 mg $148 In stock
10 mg $228 In stock
25 mg $398 In stock
50 mg $598 In stock
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

M3814 (Nedisertib, Peposertib, MSC2490484A) is a highly potent, selective, ATP-competitive and orally bioavailable inhibitor of DNA-PK with IC50 of 0.6 nM (10 uM ATP).
M3814 exhibited a high degree of selectivity when tested using a broad panel of serine/threonine, tyrosine, and lipid kinases, only 8of 284 recombinantly expressed protein/lipid kinases, including mutant kinases, were inhibited by at least 50% at 1 μmol/L M3814.
M3814 selectively inhibits DNA-PK activity and DSB repair in human cancer cell lines.
M3814 sensitizes cancer cells to IR through impaired colony outgrowth or proliferation/viability.
M3814 inhibits radiation-induced DNA-PK autophosphorylation and DSB repair in tumor xenograft models.
M3814 in combination with ionizing radiation (IR) has antitumor activity in mouse xenograft models.

Physicochemical Properties

M.Wt 481.912
Formula C24H21ClFN5O3
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(S)-{2-chloro-4-fluoro-5-[7-(morpholin-4-yl)quinazolin-4-yl]phenyl}(6-methoxypyridazin-3-yl)methanol

References

1. Harnor SJ, et al. ChemMedChem. 2017 Jun 21;12(12):895-900.
2. Zenke FT, et al. Mol Cancer Ther. 2020 May;19(5):1091-1101.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: